**Introductions**

Osimertinib is a third-generation reversible inhibitor of EGFR with clinical activity in patients who have acquired resistance to previous EGFR TKIs (N=125).

Methods

- ORCHARD is enrolling patients with EGFRm advanced NSCLC whose tumours progressed on first-line treatment.
- Patients are allocated to a treatment cohort based on their tumour molecular profile.
- Patients entered ORCHARD with a secondary or third-line EGFRm EGF inhibitor was allocated to receive osimertinib (80 mg, orally, once daily) + necitumumab (400 mg, intravenously, on Day 1 and Day 2 of a 3-week cycle).

Results and interpretation

- Secondary EGFR inhibitors included afatinib, dacomitinib and lorlatinib and were determined by next-generation sequencing of tumour tissue collected post-disease progression on first-line osimertinib.
- The primary objective of this analysis was to assess the efficacy of osimertinib + necitumumab, by evaluation of objective response rate (ORR) and overall survival in patients with advanced NSCLC included in ORCHARD.
- The probability of ORR and OS among patients with third-line treatment were assessed in strata defined by molecular profile.

Conclusions

- ORCHARD is an ongoing Phase II platform study (NCT03944772) evaluating the efficacy and safety of osimertinib in combination with necitumumab in patients with advanced NSCLC whose tumours progressed on first-line osimertinib.

Acknowledgements

This study (NCT03944772) was funded by AstaZeneca. The authors would like to acknowledge Gemma White, MSC, of AstaZeneca MedComms, an INCO Company, for medical writing support that was funded by AstaZeneca in accordance with Good Publication Practice (GPP3) guidelines (https://www.ismpp.org/gpp).

Disclosures

Presenting author (JW) reports research grants with Merck, Boehringer Ingelheim, Novartis, AstaZeneca, Revolution Medicine (not funding to institution); reports advisory role consultation fees with Novartis and Blueprint, and reports honoraria from Novartis, Genentech, EMD Serono, Jans Pharmaceuticals, Janssen, Turning Point, Biogen, Merck, Novartis, Roche, Genentech, Boehringer Ingelheim and Regeneron.

**References**


**ORCHARD: osimertinib + necitumumab in patients with advanced NSCLC whose disease progressed on first-line osimertinib**

**Objective**

- ORCHARD is an ongoing Phase II platform study (NCT03944772) evaluating the efficacy and safety of osimertinib in combination with necitumumab in patients with advanced NSCLC whose tumours progressed on this first-line treatment.

**Methods**

- ORCHARD is enrolling patients with EGFRm advanced NSCLC whose tumours progressed on first-line treatment.
- Patients are allocated to a treatment cohort based on their tumour molecular profile.
- Patients entered ORCHARD with a secondary or third-line EGFRm EGF inhibitor was allocated to receive osimertinib (80 mg, orally, once daily) + necitumumab (400 mg, intravenously, on Day 1 and Day 2 of a 3-week cycle).
- Secondary EGFR inhibitors included afatinib, dacomitinib and lorlatinib and were determined by next-generation sequencing of tumour tissue collected post-disease progression on first-line osimertinib.
- The primary objective of this analysis was to assess the efficacy of osimertinib + necitumumab, by evaluation of objective response rate (ORR) and overall survival in patients with advanced NSCLC included in ORCHARD.
- The probability of ORR and OS among patients with third-line treatment were assessed in strata defined by molecular profile.

**Results and interpretation**

- Stable disease and progressive disease were reported in patients (38%) each; 1 patient (6%) was non-evaluable.
- Patients were closed as confirmed ORR fully stop criteria was met.
- Among patients with osimertinib + necitumumab, the majority were 65 years (91.5%), male (100%), white (83.3%), and non-smoker (91.5%).

**Conclusions**

- ORCHARD is an ongoing Phase II platform study (NCT03944772) evaluating the efficacy and safety of osimertinib in combination with necitumumab in patients with advanced NSCLC whose tumours progressed on this first-line treatment.

**Acknowledgements**

This study (NCT03944772) was funded by AstaZeneca. The authors would like to acknowledge Gemma White, MSC, of AstaZeneca MedComms, an INCO Company, for medical writing support that was funded by AstaZeneca in accordance with Good Publication Practice (GPP) guidelines (https://www.ismpp.org/gpp/).

**Disclosures**

Presenting author (JW) reports research grants with Merck, Boehringer Ingelheim, Novartis, AstaZeneca, Revolution Medicine (not funding to institution); reports advisory role consultation fees with Novartis and Blueprint, and reports honoraria from Novartis, Genentech, EMD Serono, Jans Pharmaceuticals, Janssen, Turning Point, Biogen, Merck, Novartis, Roche, Genentech, Boehringer Ingelheim and Regeneron.

**References**